{"organizations": [], "uuid": "3f0519a032980dd2dde160055c7f7d1f0d9997d3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-asit-biotech-announces-validation/brief-asit-biotech-announces-validation-of-its-patient-blood-cell-in-vitro-selection-platform-idUSFWN1S80RE", "country": "US", "domain_rank": 408, "title": "BRIEF-Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.169, "site_type": "news", "published": "2018-05-02T13:38:00.000+03:00", "replies_count": 0, "uuid": "3f0519a032980dd2dde160055c7f7d1f0d9997d3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-asit-biotech-announces-validation/brief-asit-biotech-announces-validation-of-its-patient-blood-cell-in-vitro-selection-platform-idUSFWN1S80RE", "ord_in_thread": 0, "title": "BRIEF-Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform", "locations": [], "entities": {"persons": [], "locations": [{"name": "ghent", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - ASIT BIOTECH SA:\n* ANNOUNCES VALIDATION OF ITS PATIENT BLOOD CELL IN VITRO SELECTION PLATFORM FOR ITS NEW PRODUCT CANDIDATES AND FILING OF A EUROPEAN PATENT APPLICATION\n* DURING A FIRST PHASE III TRIAL DURING A FIRST PHASE III TRIAL (BTT009) CLINICAL EFFICACY OF GP-ASIT+ WAS STATISTICALLY SIGNIFICANTLY CONFIRMED\n* EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAI EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAINED ON GROUP OF PATIENTS TREATED AT GHENT UNIVERSITY HOSPITAL\n* SELECTION METHOD DEVELOPED BY ASIT BIOTECH HAS BEEN CLAIMED IN A PATENT APPLICATION FILED IN EUROPE ON 30 APRIL 2018\n* PATENT SAFEGUARDS ASIT BIOTECHâ€™S FUTURE DEVELOPMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T13:38:00.000+03:00", "crawled": "2018-05-03T12:34:13.018+03:00", "highlightTitle": ""}